@Article{,
AUTHOR = {Bassem Toeama, Nathan Perlis, Paul Grootendorst, William Orovan, Emmanuel Papadimitropoulos},
TITLE = {A costing and health-related quality of life study of high intensity focused ultrasound in primary treatment of localized low or intermediate risk prostate cancer in Ontario},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {4},
PAGES = {11963--11970},
URL = {http://www.techscience.com/CJU/v31n4/59578},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Prostate cancer is the third leading
cause of death from cancer among Canadian men. High
intensity focused ultrasound (HIFU) is a novel approach
for primary treatment of localized prostate cancer. Little
is known, however, about its costs. We aimed to collect
the direct costs and health-related quality of life (HRQoL)
data of HIFU in primary treatment of localized low and
intermediate risk prostate cancer in Ontario.<br/>
<b>Materials and methods:</b> We collected direct costs
and HRQoL data of 20 patients with localized low or
intermediate risk prostate cancer who received whole
gland HIFU at a privately owned clinic in Ontario.
We compared the direct costs of HIFU, open radical
prostatectomy (ORP), robot assisted radical prostatectomy
(RARP), and external beam radiation therapy (RT) in primary treatment of localized low and intermediate risk
prostate cancer.<br/>
<b>Results:</b> The average direct costs of HIFU, ORP, RARP,
and RT per case in 2023 are $14,886.78, $14,192.26,
$21,794.55, and $17,377.51, respectively. The median
and interquartile range (IQR) of the study participants’
age and HRQoL data prior to the HIFU procedure were
64.5 (11.25) years, 94.5 (8.65), 38.5 (4), 6.0 (4.46), and
22.5 (8.32), respectively.<br/>
<b>Conclusion:</b> Our healthcare payer’s perspective costing
study revealed median direct costs per case of HIFU
and favorable HRQoL outcomes compared to other
treatment options for primary treatment of localized
low and intermediate risk prostate cancer in Ontario. A
health economic model is warranted to analyze the cost
effectiveness of HIFU compared to other treatment options
in primary treatment of localized low and intermediate
risk prostate cancer.},
DOI = {}
}